Story perspectives

FDA Grants Limited Fast-Track Daraxonrasib Approval, 13-Month Survival

5/30/2026

Summary

Story summary

FDA granted limited fast-track approval for daraxonrasib on April 30, allowing access though most physicians cannot yet obtain it.
The Phase 1/2 trial reported a median overall survival of 13.2 months for pancreatic cancer patients.
Severe side effects affected about 30 % of participants, with 90 % developing rash and half experiencing diarrhea or mouth inflammation.
Experts warned that limited availability, uncertain pricing and oral dosing could create equity and insurance challenges for patients.

1 of 1

Story summary

FDA granted limited fast-track approval for daraxonrasib on April 30, allowing access though most physicians cannot yet obtain it.
The Phase 1/2 trial reported a median overall survival of 13.2 months for pancreatic cancer patients.
Severe side effects affected about 30 % of participants, with 90 % developing rash and half experiencing diarrhea or mouth inflammation.
Experts warned that limited availability, uncertain pricing and oral dosing could create equity and insurance challenges for patients.